


Cystic Fibrosis Therapeutics Market Is Expected To Reach \$9,277.3 Million By 2026, Registering a CAGR of 9.2%

Increase in R&D investments made by government in the healthcare sector drives the cystic fibrosis therapeutics market growth.

PORTLAND, OREGON, US, January 25, 2022 /EINPresswire.com/ -- According to the "Cystic Fibrosis (CF) Therapeutics Market: : Global Opportunity Analysis and Industry Forecast, 2019-2026", report published by the Allied Market Research, the study presents impending revenue forecast of the industry for the next few years coupled with imminent market trends and opportunities. Moreover, the study also doles out different logical tables and graphs to identify the complexities of the market.



The global cystic fibrosis therapeutics market size was valued at \$4,615.4 million in 2018 and is expected to reach \$9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026.

Cystic fibrosis is a hereditary disorder, which majorly affects lungs and other body parts such as pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is located in chromosome number 7, and is responsible for the regulation of sweat, mucus, and body secretions. However, mutation of this gene leads to absence of CFTR activity, which in turn results in loss of chloride and alters the protein structure.

Download PDF Boucher: <https://www.alliedmarketresearch.com/request-sample/5499>

The global cystic fibrosis therapeutics market is expected to witness significant growth during the forecast period majorly due to availability of personalized drug therapy & molecular prosthetics for the treatment of cystic fibrosis. Furthermore, rise in prevalence of cystic fibrosis and surge in awareness about cystic fibrosis across the globe boost the cystic fibrosis market trend. For

instance, according to the Cystic Fibrosis Foundation Patient Registry, in the U.S. more than 30,000 people are living with cystic fibrosis and more than 70,000 worldwide.

The global cystic fibrosis therapeutic market is segmented on the basis of drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. By top selling drug, the market is segregated into pulmozyme, Creon, kalydeco, cayston, azithromycin, tobramycin and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Surge in national newborn screening program in the UK propels the market growth. In addition, many companies are involved in developing drugs for individuals who do not get benefitted with CFTR drugs. However, North America is projected to grow at the highest CAGR during the forecast period.

Purchase Inquiry: <https://www.alliedmarketresearch.com/purchase-enquiry/5499>

Key Benefits:□

- The cystic fibrosis therapeutics market share is based on a comprehensive analysis of key developments in the cystic fibrosis industry.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global cystic fibrosis therapeutics market.
- The cystic fibrosis therapeutics market trends are studied from 2018 to 2026.
- Information about key drivers, restrains, and opportunities and their impact analysis on the cystic fibrosis therapeutics market size is provided.
- Porter's five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
- The quantitative analysis of the global cystic fibrosis therapeutics market forecast from 2019 to 2026 is provided to determine the market potential.

The research offers an extensive analysis of key players active in the global cystic fibrosis therapeutics market include Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.

Request Customization: <https://www.alliedmarketresearch.com/request-for-customization/5499>

Other Trending Reports:

[Biochemical Reagents Market](#)
[Cell Dissociation Market](#)

About Us

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
Allied Analytics LLP
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561433302>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.